Injectable Lipid-Lowering Agents and Their Public Health Benefits

Abstract

Cardiovascular disease remains a leading cause of mortality worldwide, with elevated levels of low-density lipoprotein cholesterol (LDL-C) and lipoprotein(a) identified as key modifiable risk factors. Effective lipid management is a cornerstone of both primary and secondary prevention strategies. While oral lipid-lowering therapies, such as statins and ezetimibe, are considered the standard of care, their efficacy may be limited in certain high-risk or treatment-resistant populations. In this context, injectable lipid-lowering agents—particularly PCSK9 inhibitors and inclisiran—have emerged as potent alternatives, offering sustained LDL-C reduction and the potential for long-term public health benefits. This article reviews their mechanisms of action, clinical effectiveness, trends in public health implementation, and considerations for reimbursement under national health coverage schemes, supported by current scientific evidence.